Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Avodart approved for hair loss in men age 18 to 50
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Nov 12, 2014 05:42:25
GlaxoSmithKline Korea said Avodart is now approved for the treatment of male pattern hair loss in men aged 18 to 50 years by the Ministry of Food and Drug Safety.

Avodart was approved for the treatment of androgenetic alopecia in men aged 18 to 41 years. Now the indication has been expanded.

An official of GSK Korea said, “There had been many studies of Avodart to prove safety and efficacy to treat hair loss in various age groups. Now we can share the benefit of the studies.”

The latest study of Avodart was published in Journal of the American Academy of Dermatology (JAAD).
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com